A new systems-level approach to cancer therapeutics
Aligned against cancer
The Challenge
Cancer cells in solid tumors are protected by a complex ecosystem
Our approacH
STEM3: The first integrated, systems-level oncology solution
STEM3: System for Tumor Ecosystem Modulation
01
map
Explore the broader tumor landscape and potential druggable matrix targets using:
  • Multi-modal human tissue data
  • Matrix biology
  • Phenomics
02
MODEL
Create proprietary cancer type-specific ecosystem models to discover novel biology
  • Unique AI/ML models incorporating data from across the ecosystem
  • Validate with gold-standard in vivo models
03
MODULATE
Rapidly (in days) compare genetic and compound phenotypes to identify compound starting points:
  • Improved drug candidates
  • Better clinical-stage results
  • Improved patient outcomes
The STEM3 platform allows us to target matrix-rich solid tumors with some of the worst survival rates
Solid Tumor Survival Rates:
22%
Liver cancer
13%
Pancreatic cancer
6-22%
Glioblastoma
15%
Sarcoma
TEAM
A proven team with experience in cancer biology, drug discovery AI, drug development, and company building
Anne Carpenter, PhD
Co-founder & Chair SAB
  • Institute Scientist (MIT)
  • $RXRX SAB
  • Co-creator: Cell Painting assay & CellProfiler
  • Top-100 AI Leaders in Drug Discovery & Healthcare
T. S. Karin Eisinger, PhD
Co-founder & CEO
  • Former Ann B. Young Asst. Professor of Cancer Research (UPenn)
  • NCI- and DoD-funded cancer researcher
Ashley M. Fuller, PhD
Co-founder & CSO
  • ACS BrightEdge entrepreneurship fellow
  • Former American Cancer Society post-doctoral fellowship grantee (UPenn)
Tim Considine, JD
Advisor
  • 30+ years experience drug development with multiple approvals
  • Former SVP Strategic Development $RXRX
  • Former COO Known Medicine
Ying Liu, PhD
Principal Scientist
- Team lead
  • Cancer researcher with 10+ years of project management experience
  • Expertise in solid tumor matrix biology and methods development
Publications
Read the foundational research behind our work:
News
See our latest updates
We’d love to hear from you

Let's have a conversation

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.